Patient group
Patientinnen und Patienten mit Molybdän-Cofaktor-Mangel (MoCD) Typ A
completed2025-03-15D series
Fosdenopterin
Molybdän-Cofaktor-Mangel Typ A
Open official case page ↗
- Brand
- Nulibry
- Manufacturer
- Sentynl Therapeutics
G-BA action
final resolution
2025-09-04
Arzneimittel-Richtlinie/Anlage XII: Fosdenopterin (Molybdän-Cofaktor-Mangel Typ A)
Evidence-checked summary
The G-BA found a hint of non-quantifiable added benefit for Patientinnen und Patienten mit Molybdän-Cofaktor-Mangel (MoCD) Typ A. The G-BA issued a final resolution on 2025-09-04. The official page states that it took effect as follows: 04.09.2025. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.
Final benefit result
G-BA result by patient group
Official case record
What happened, in source order
No inferred stages
Consultation record
Oral hearing and Wortprotokoll
2025-07-28
107 parsed turns
Oral hearing: Fosdenopterin (Molybdän-Cofaktor-Mangel Typ A)
Official Wortprotokoll · 16 pages
IQWiG comparison
Assessment record versus G-BA action
IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.
No IQWiG assessment reference is present on the validated official case page. This is an explicit absence, not a broken graph link.
G-BA decisions
Distinct actions and documents
2025-09-04
final resolution
Arzneimittel-Richtlinie/Anlage XII: Fosdenopterin (Molybdän-Cofaktor-Mangel Typ A)
The G-BA found a hint of non-quantifiable added benefit for Patientinnen und Patienten mit Molybdän-Cofaktor-Mangel (MoCD) Typ A. The G-BA issued a final resolution on 2025-09-04. The official page states that it took effect as follows: 04.09.2025. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
3 official documents · 4 cited claims
Official sources
Case document package
official case pageOfficial G-BA case pageOpen ↗gba assessment amendmentAmendment zur Nutzenbewertung des G-BAOpen ↗iqwig cost assessmentBewertung der Therapiekosten und Patientenzahlen IQWiGOpen ↗gba assessmentNutzenbewertung G-BAOpen ↗hearing transcriptWortprotokollOpen ↗decision textBeschlusstextOpen ↗decision rationaleTragende Gründe zum BeschlussOpen ↗summary documentationZusammenfassende DokumentationOpen ↗
Generic graph relations · 5
HAS ASSOCIATED DECISIONArzneimittel-Richtlinie/Anlage XII: Fosdenopterin (Molybdän-Cofaktor-Mangel Typ A)HAS HEARINGOral hearing: Fosdenopterin (Molybdän-Cofaktor-Mangel Typ A)OWNS DOCUMENTAmendment zur Nutzenbewertung des G-BAOWNS DOCUMENTBewertung der Therapiekosten und Patientenzahlen IQWiGOWNS DOCUMENTNutzenbewertung G-BA